Abeona Therapeutics

Abeona Therapeutics is developing gene therapy-based potential cures for the deadly childhood diseases Sanfilippo (SF) Syndrome Type A and Type B. Its multi-platform expertise across the manufacture, delivery, development, and discovery of the novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company’s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery.

Abeona Therapeutics headquartered in New York, New York, United States, North America, operates in the Biotechnology, Health Care, Manufacturing, Medical Device, Genetics sector. The company focuses on Biotechnology and has secured $111.7B in funding across 260 round(s). With a team of 51-100 employees, Abeona Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - Abeona Therapeutics, raised $750.0K. Discover more about their projects, partnerships, and impact on our platform.